Eli Lilly falls after weight-loss drug sales miss expectations

Shares of drugmaker Eli Lilly LLY.N fall 4.3% to $860.72 premarket

Q1 sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates

Zepbound posted Q1 sales of $2.31 billion compared with analysts' average estimate of $2.33 billion, as per data compiled by LSEG

Co also cuts annual adj. profit forecast to between $20.78 and $22.28 per share from $22.50 and $24 previously

Sales of diabetes drug Mounjaro came in at $3.84 billion, compared with estimates of $3.80 billion- LSEG

Up to last close, LLY was up 16.4% YTD